What Is The Comparative Market Size Outlook For The Gastric Cancer Diagnostic Market Over The 2026–2030Timeframe?
The gastric cancer diagnostic market size has grown strongly in recent years. It will grow from $2.78 billion in 2025 to $2.98 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to limited availability of fluorescent probes, reliance on traditional single-color FISH methods, growing genetic research initiatives, increasing hospital and laboratory infrastructure, adoption of basic cytogenetic diagnostics.
The gastric cancer diagnostic market size is expected to see strong growth in the next few years. It will grow to $3.87 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to development of multiplex and high-throughput probes, rising demand for precision medicine, expansion of genetic and pharmaceutical research, technological advancements in imaging and quantification, increasing regulatory compliance and quality standards. Major trends in the forecast period include rising adoption of multiplex and high-throughput fish probes, expansion of genetic and molecular diagnostic applications, growing use in clinical and pharmaceutical research, integration with advanced imaging and analysis technologies, increased focus on probe accuracy and sensitivity.
Claim Your Free Report Sample Today:
What Significant Demand Drivers Are Anticipated To Influence The Gastric Cancer Diagnostic Market Over The Coming Years?
The rising incidence of gastric cancer is expected to propel the growth of the gastric cancer diagnostic market going forward. Gastric cancer refers to a malignant tumor in the stomach lining, where cells grow uncontrollably, forming a mass that can invade nearby tissues and spread to other parts of the body. The rising incidence of gastric cancer is due to unhealthy dietary habits, as high consumption of salted, smoked, and processed foods increases stomach lining damage and cancer risk. Gastric cancer diagnostic aids in gastric cancer diagnosis by enabling early detection of malignant lesions, making it ideal for timely treatment and improved patient outcomes. They enhance clinical efficiency by providing accurate and rapid results, supporting better disease management. For instance, in May 2024, according to the American Cancer Society, a US-based nonprofit organization, the number of new stomach cancer cases reached 26,890 in 2024, an increase from 26,500 cases in 2023. Therefore, the rising incidence of gastric cancer is driving the growth of the gastric cancer diagnostic market.
What Segment Divisions Provide The Most Valuable Insights Into The Gastric Cancer Diagnostic Market?
The gastric cancer diagnostic market covered in this report is segmented –
1) By Diagnostic Type: Endoscopy, Imaging, Biopsy, Laboratory Tests, Biomarker-Based Testing
2) By Product: Reagents And Consumables, Instruments
3) By Technology: Molecular Diagnostics, Immunoassays, Next-Generation Sequencing, Other Technologies
4) By Application: Early Diagnosis, Screening, Monitoring
5) By End User: Hospitals, Clinics, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Endoscopy: Conventional Endoscopy, Chromoendoscopy, Narrow Band Imaging, Confocal Laser Endomicroscopy, Capsule Endoscopy
2) By Imaging: Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound
3) By Biopsy: Forceps Biopsy, Needle Biopsy, Endoscopic Ultrasound-Guided Biopsy, Laparoscopic Biopsy
4) By Laboratory Tests: Blood Tests, Stool Tests, Urea Breath Test, Serology
5) By Biomarker-Based Testing: Genetic Testing, Protein Biomarker Testing, Circulating Tumor DNA Testing, Microribonucleic Acid Testing
Which Trends Are Currently Influencing The Direction Of The Gastric Cancer Diagnostic Market?
Major companies operating in the gastric cancer diagnostic market are focusing on developing innovative diagnostic tools, such as artificial intelligence-based endoscopic diagnostic support devices, to enhance early detection and accuracy. Artificial intelligence-based endoscopic diagnostic support devices are AI-powered tools that assist in detecting and assessing gastrointestinal abnormalities during endoscopy. For instance, in March 2024, AI Medical Service Inc., a Japan-based medical technology company, launched GastroAI-model G, an AI-powered endoscopic diagnostic support system. This system assists gastroenterologists during endoscopy by analyzing video images in real time to identify potential cancerous lesions. It uses deep learning to detect suspicious areas indicative of early gastric cancer, which may require biopsy or further examination. When such lesions are identified, the system instantly alerts the physician by highlighting the area with a rectangle on the endoscopic screen, improving diagnostic accuracy and enabling early cancer detection.
Who Are The Key Companies Actively Operating Within The Gastric Cancer Diagnostic Market?
Major companies operating in the gastric cancer diagnostic market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Qiagen N.V., DiaSorin S.p.A, Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Foundation Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Fujirebio Inc., MiRXES Pte Ltd., BIOCEPT Inc., Pillar Biosciences Inc.
Get Your In-Depth Gastric Cancer Diagnostic Market Report Now:
Which Regions Are Generating The Highest Demand Within The Gastric Cancer Diagnostic Market?
North America was the largest region in the gastric cancer diagnostic market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment